Jounce Therapeutics (JNCE) Covered By H.C. Wainwright with $33 Target; A.G. BARR p.l.c. (LON:BAG) Had 2 Analysts Last Week

A.G. BARR p.l.c. (LON:BAG) Logo

H.C. Wainwright issued a Buy rating on Jounce Therapeutics (JNCE). The firm started coverage on shares of JNCE in a a report issued to clients and investors on Friday, 27 April. H.C. Wainwright’s PT suggests upside of 60.43% from the company’s current price.

Among 9 analysts covering Barr A G PLC (LON:BAG), 2 have Buy rating, 1 Sell and 6 Hold. Therefore 22% are positive. Barr A G PLC had 88 analyst reports since July 24, 2015 according to SRatingsIntel. Barclays Capital maintained A.G. BARR p.l.c. (LON:BAG) rating on Friday, January 15. Barclays Capital has “Equal Weight” rating and GBX 560 target. The rating was maintained by Numis Securities with “Hold” on Friday, July 24. On Wednesday, August 3 the stock rating was maintained by JP Morgan with “Overweight”. The firm earned “Overweight” rating on Tuesday, February 2 by JP Morgan. As per Friday, July 24, the company rating was maintained by Investec. The rating was upgraded by Berenberg on Thursday, December 15 to “Hold”. The stock of A.G. BARR p.l.c. (LON:BAG) earned “Buy” rating by Investec on Wednesday, August 2. The stock of A.G. BARR p.l.c. (LON:BAG) earned “Hold” rating by Whitman Howard on Wednesday, December 14. As per Friday, July 24, the company rating was maintained by Shore Capital. The rating was maintained by Berenberg on Thursday, October 27 with “Sell”. See A.G. BARR p.l.c. (LON:BAG) latest ratings:

13/04/2018 Broker: Berenberg Rating: Hold Old Target: GBX 550.00 New Target: GBX 575.00 Reiteration
14/02/2018 Broker: JP Morgan Rating: Underweight Old Target: GBX 630.00 New Target: GBX 570.00 Downgrade
01/02/2018 Broker: Numis Securities Rating: Hold Old Target: GBX 675.00 New Target: GBX 675.00 Maintain
29/01/2018 Broker: Societe Generale Rating: Buy New Target: GBX 758.00 Upgrade
02/01/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 610.00 New Target: GBX 630.00 Reiteration
12/12/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 610.00 New Target: GBX 630.00 Maintain

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $667.76 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

Analysts await Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report earnings on May, 8. They expect $-0.31 EPS, down 1,450.00% or $0.29 from last year’s $-0.02 per share. After $-0.34 actual EPS reported by Jounce Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -8.82% EPS growth.

Among 5 analysts covering Jounce Therapeutics (JNCE), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Jounce Therapeutics has $35.0 highest and $28.0 lowest target. $30.33’s average target is 47.45% above currents $20.57 stock price. Jounce Therapeutics had 8 analyst reports since February 21, 2017 according to SRatingsIntel. Robert W. Baird maintained it with “Buy” rating and $30.0 target in Tuesday, September 12 report. Robert W. Baird initiated the shares of JNCE in report on Tuesday, February 21 with “Outperform” rating. As per Tuesday, February 21, the company rating was initiated by Wells Fargo. The firm earned “Overweight” rating on Tuesday, February 21 by JP Morgan. As per Thursday, March 8, the company rating was maintained by Robert W. Baird. The firm earned “Buy” rating on Wednesday, June 7 by Cowen & Co. Cowen & Co maintained Jounce Therapeutics, Inc. (NASDAQ:JNCE) on Monday, November 13 with “Buy” rating.

The stock increased 6.64% or $1.28 during the last trading session, reaching $20.57. About 299,319 shares traded. Jounce Therapeutics, Inc. (JNCE) has declined 9.84% since April 27, 2017 and is downtrending. It has underperformed by 21.39% the S&P500.

A.G. BARR p.l.c., together with its subsidiaries, makes, distributes, and sells soft drinks in the United Kingdom and internationally. The company has market cap of 782.29 million GBP. The firm operates through Carbonates, Still Drinks and Water, and Other divisions. It has a 21.43 P/E ratio. It offers flavored drinks, fruit purées, cocktail mixers and syrups, carbonated soft drinks, energy drinks, still and juice drinks, ice creams, fruit drinks, iced tea, and water.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Chart